Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

← catalyst calendar

NCT04454658 · readout ≤ 165 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

21actual

Sites

Countries

Argentina, Australia, Brazil +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-11-11

actual

When the study began enrolling

Primary completion

Jan 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2027

estimated

The whole study's end, after follow-up

First posted

2020-07-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-07-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Myelofibrosis (MF)

Interventions

Drug: ABBV-744
Drug: Navitoclax — also filed as ABT-263
Drug: Ruxolitinib

Primary outcome

what the primary-completion date above is the date OF

Percentage of Participants With Adverse Events

measured Up to Approximately 1 year from start of study

Publications

PMID 41843794 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed